Sorafenib

Catalog No.S7397 Synonyms: BAY 43-9006

Sorafenib Chemical Structure

Molecular Weight(MW): 464.82

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

9 Customer Reviews

  • Inhibition of the MAPK signaling pathway results in downregulation of Plk-1 protein expression. (a) WB analysis for Plk-1 protein after treatment of human melanoma cell lines M14 and WM-115 with MEK 1/2 inhibitor PD98059 (10 μM), JNK inhibitor (16 μM), p38 inhibitor SB203580 (20 μM), and multikinase inhibitor sorafenib (10 μM) for 48 h showing significant reduction in the expression of Plk-1 protein after 48 hours. (b) Annexin V/PI staining of cells treated with MAPK inhibitors and induction of apoptosis. JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK 1/2, mitogen-activated protein kinase kinase 1/2; Plk-1, polo-like kinase 1; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. Sorafenib purchased from Selleck.

    (A) were exposed to 200 uM gentamicin for various time periods. Immunoreactivity for phosphorylated JNK (green) and c-Jun (blue) in hair cells increased in a time-dependent manner. B. Hair cells from explants pre-treated with 500 nM sorafenib displayed a near complete inhibition of JNK activation at all time points analyzed.

    J Neurosci 2013 33(7), 3079-93. Sorafenib purchased from Selleck.

  • Sorafenib in combination with metformin or the AMPK activator salicylate enhances AMPK activation. a, b, AMPK activation with the combination of sorafenib and metformin in LKB1 mutant KRAS mutant (A549 and H460) NSCLC cells (a), LKB1 wild-type KRAS mutant (H358) (b, left panel) or LKB1 mutant KRAS wild-type (H838) NSCLC cells (b, right panel). Cells were treated for 48 hr with sorafenib (1-3 uM), metformin (1–1.5 mM) or the combination of sorafenib and metformin with the same concentrations as were used for the individual treatments. c, AMPK activation with the combination of sorafenib and salicylate in LKB1 mutant KRAS mutant (A549 and H460) or LKB1 mutant KRAS wild-type (H838) NSCLC cells. Cells were treated for 48 hr with sorafenib (1–3 uM), salicylate (1–1.5 mM) or the combination of sorafenib and salicylate with the same concentrations as were used for the individual treatments. Cell lysates were harvested for western blot analysis and probed with the indicated antibodies.

    Int J Cancer 2012 10.1002/ijc.29113.. Sorafenib purchased from Selleck.

    Involvement of EV linc-VLDLR in tumor cell responses to chemotherapy. Cells were incubated with sorafenib, camptothecin, or doxorubicin. EVs were obtained after 24 hours, and qRT-PCR was performed for linc-VLDLR. The bars represent the mean ?SEM of the increase in cell viability from 3 independent studies. *, P < 0.05.

    Mol Cancer Res 2014 12(10), 1377-87. Sorafenib purchased from Selleck.

  • HCC cell-derived exosomes reverse sorafenib-induced apoptosis in hepatoma carcinoma cells in vivo. a Tumors from mice treated with PBS (Control), sorafenib (Sora), sorafenib + LO2-exosomes (Sora + LO2 exo), sorafenib + MHCC-97 L-exosomes (Sora + 97 L exo), and sorafenib + MHCC-97H-exosomes (Sora + 97H exo) were paraffin-embedded and sectioned, followed by staining of apoptotic cell by using TUNEL assays.

    J Exp Clin Cancer Res, 2016, 35(1):159. Sorafenib purchased from Selleck.

    Sorafenib and PX-866 interact to suppress tumor growth in vivo. Mice were PO administered vehicle diluent, sorafenib (25 mg/kg), PX-866 (2 mg/kg), or the drug combination QD for 3 days. Animals were monitored daily and tumor volume determined every fifth day. Tumors from animals were isolated at day 15 and fixed, sectioned (10-um), and stained against proliferation (Ki67 staining), phospho-ERK1/2 and phospho-AKT staining, the levels of tumor cell apoptosis/cleaved caspase 3, as well as with H&E and 4′,6-diamidino-2-phenylindole (DAPI).

    Mol Pharmacol 2013 84(4), 562-71. Sorafenib purchased from Selleck.

  • Effects of sorafenib or sunitinib on LicA-induced cell death, ER stress responses, PLCc1, Ca2+, and ROS in HepG2 cells. HepG2 cells were pretreated with sorafenib or sunitinib for 1 h, then treated with LicA or TG for 1 h (for P-eIF2a and P-PLCc1) or 24 h (for CHOP, ATF6a(p90), and caspase-4). The cell lysates were subjected to Western blot analyses using antibodies against CHOP, ATF6a(p90), caspase-4(C), P-eIF2a, and b-actin.

    Apoptosis 2014 19(4), 682-97. Sorafenib purchased from Selleck.

    PLoS One 2013 8(1), e54595. Sorafenib purchased from Selleck.

  • (C) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in HUH-7 and R-HUH-7 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (D) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in SK-HEP-1 and R-SK-HEP-1 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (E) HUH-7 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. (F) SK-HEP-1 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. Data were expressed as mean ± standard deviation of each experiment in triplicate. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. Sorafenib purchased from Selleck.

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
Targets
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
In vitro

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NIG1TXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMECwNFA{ODNizszN Mmn6V2FPT0WU
MONO-MAC-6 MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUixW2hiUUN3ME2wMlAxPDF6IN88US=> NGHJUmtUSU6JRWK=
ALL-PO MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\1dVhPUUN3ME2wMlA{OTh2IN88US=> NWLodolNW0GQR1XS
NKM-1 M160Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDhTWM2OD1yLkC3OFE3KM7:TR?= Ml;QV2FPT0WU
CGTH-W-1 MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn2[Y5KSzVyPUCuNlUxOjJizszN MnnlV2FPT0WU
BB65-RCC M{D4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPL[nBKSzVyPUCuOFcxPzNizszN M4jmNnNCVkeHUh?=
NOS-1 NWGx[oJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zleGlEPTB;MD61OlM3KM7:TR?= MljWV2FPT0WU
SH-4 NWrP[Fg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzme4JKSzVyPUCuOlU3OTNizszN M1\ZeHNCVkeHUh?=
HOP-62 Moi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPvR5A5UUN3ME2wMlg2ODh6IN88US=> NHnjdG1USU6JRWK=
HCC2998 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjldVFCUUN3ME2wMlg5QDF6IN88US=> NGK5RYZUSU6JRWK=
GDM-1 NYrTN3FnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwOUC2PVgh|ryP M3zNTXNCVkeHUh?=
KM12 NGjOWJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDS[|hvUUN3ME2xMlAzODl6IN88US=> M3zJcnNCVkeHUh?=
LB2518-MEL M{LhXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFwMkC4NFkh|ryP NWDzTWVEW0GQR1XS
NCI-H1436 MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIji[I1KSzVyPUGuNlE3PzhizszN NEG3PI1USU6JRWK=
EM-2 NF72dGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[0XGhUUUN3ME2xMlM2PTd6IN88US=> NFe5OoRUSU6JRWK=
LAMA-84 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT3c3pKSzVyPUGuN|c3PDhizszN MVnTRW5ITVJ?
KG-1 M{f1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXezXoduUUN3ME2xMlQ4QTN3IN88US=> MmnaV2FPT0WU
A388 M4PNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Pi[2lEPTB;MT61PVE3PSEQvF2= M1rxTXNCVkeHUh?=
no-10 Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTkTWM2OD1zLk[xO|I3KM7:TR?= MkPQV2FPT0WU
SF126 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojrTWM2OD1zLk[zPFEzKM7:TR?= MmXqV2FPT0WU
MEG-01 NHq1Z2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTFwOEC5PEDPxE1? NIH5Z2pUSU6JRWK=
A3-KAW MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2qzXGlEPTB;MT64PFQzKM7:TR?= NV[5VnlFW0GQR1XS
D-247MG NFLUUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\XdWlEPTB;Mj6xOFQ5KM7:TR?= NULtN4hCW0GQR1XS
OVCAR-4 M1v6b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlThTWM2OD1{LkKxN|k{KM7:TR?= M4LZSnNCVkeHUh?=
NCI-SNU-1 M3;US2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fWbWlEPTB;Mj6zNVYzKM7:TR?= MlnnV2FPT0WU
NCI-H2171 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJwM{m3OlQh|ryP MlG0V2FPT0WU
SIG-M5 M2nwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJwNEKyOFIh|ryP NU\wfWtXW0GQR1XS
BE-13 NH3ieppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\jS5dLUUN3ME2yMlY6PjB7IN88US=> NX7HSIprW0GQR1XS
K052 MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrlPYxKSzVyPUKuO|Q3OTZizszN MkHUV2FPT0WU
L-540 NHu3WpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnqTWM2OD1{Lke1O|g6KM7:TR?= MXLTRW5ITVJ?
KMOE-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJwOEGzOUDPxE1? NXvEcpZQW0GQR1XS
MFH-ino NVfZdow2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJwOUKxPFUh|ryP M{j1[nNCVkeHUh?=
HL-60 MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTNwME[yPVkh|ryP Mn3jV2FPT0WU
HCC2218 MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3BSHZ4UUN3ME2zMlEzODB|IN88US=> NGjT[lhUSU6JRWK=
TE-5 M175SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;xTWM2OD1|LkGzNVYzKM7:TR?= MoX6V2FPT0WU
MZ1-PC NF\zTmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPs[WRKSzVyPUOuOFc2ODlizszN NGX5VIRUSU6JRWK=
MRK-nu-1 NHO0XYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTNwNkG0Olgh|ryP NFvScZNUSU6JRWK=
MZ7-mel M1TT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD6dHV1UUN3ME2zMlY3ODl7IN88US=> M3uwW3NCVkeHUh?=
BC-1 NHfXXVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjRe3RKSzVyPUOuO|QxOiEQvF2= NGTJc3dUSU6JRWK=
ST486 Mm[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEO5NGZKSzVyPUOuPFM3PzNizszN NFnDUYFUSU6JRWK=
KS-1 NXnhTGZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTNwOEixPVgh|ryP MXPTRW5ITVJ?
SK-NEP-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTRwMU[4NVUh|ryP NHrxNHJUSU6JRWK=
BC-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\FOGlEPTB;ND6yN|M6OSEQvF2= NFnTZnNUSU6JRWK=
NCI-H1581 NIfBNHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTpTm9[UUN3ME20MlI5Pzl6IN88US=> M1TIWHNCVkeHUh?=
MHH-PREB-1 M{\vW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrieox4UUN3ME20MlQxPDh2IN88US=> NHvqToNUSU6JRWK=
NOMO-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz1TWM2OD12LkS4PVA2KM7:TR?= NYLJSHdWW0GQR1XS
QIMR-WIL NXnzNYY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTVwMEeyPVQh|ryP M3K3OHNCVkeHUh?=
SF539 MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vM[mlEPTB;NT6xN|IzPyEQvF2= NWDCTI97W0GQR1XS
TE-12 Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\zbYxKSzVyPUWuNlQ6OjlizszN NX7RUmJMW0GQR1XS
NCI-H510A MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD4XYN1UUN3ME21MlQyPjh3IN88US=> MVXTRW5ITVJ?
JAR M1zNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXKdpZKSzVyPUWuOVA5OjRizszN NIjZdIJUSU6JRWK=
no-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TpRWlEPTB;NT63N|U3QCEQvF2= M3PSXHNCVkeHUh?=
BV-173 M3vQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\QeldHUUN3ME21Mlk2Pjh{IN88US=> M{X4cXNCVkeHUh?=
SR Mk\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHYTWM2OD14LkCwOlc5KM7:TR?= Mkm3V2FPT0WU
MOLT-16 NGDqdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\ZNHk1UUN3ME22MlI2OjZ4IN88US=> MkexV2FPT0WU
MZ2-MEL Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTZwM{G4N|kh|ryP NG[1OWxUSU6JRWK=
SW954 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\CWmZKSzVyPU[uOFU5PjZizszN MVjTRW5ITVJ?
ML-2 NIfT[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnNS|lnUUN3ME22MlUzQDR7IN88US=> NHXUeJdUSU6JRWK=
OCI-AML2 NYXNOVhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\HflFKSzVyPU[uOlExPjJizszN MWjTRW5ITVJ?
SIMA MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITvcWJKSzVyPUeuNFAyODFizszN MofQV2FPT0WU
DOHH-2 MmTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\S[ZBKSzVyPUeuNFU3PzZizszN NH[5PGVUSU6JRWK=
697 NEL4VYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHm[oZzUUN3ME23MlA2QTh7IN88US=> NIPQbGlUSU6JRWK=
NB1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHp[WhKSzVyPUeuOFA1ODdizszN NXfQfW1GW0GQR1XS
D-392MG M4DicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTdwNkK2OlMh|ryP NE\3XW5USU6JRWK=
ES8 NV;xN|V7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTdwN{[1NFMh|ryP M2S3bnNCVkeHUh?=
RPMI-8226 NEjj[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrzflRKSzVyPUeuPFQ2OTFizszN M3jRWXNCVkeHUh?=
IST-MEL1 MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3rPG13UUN3ME24MlQxODB{IN88US=> MmXzV2FPT0WU
NB14 MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDjV2dTUUN3ME24MlY{OTN|IN88US=> NVvwbmk3W0GQR1XS
HD-MY-Z NYXXZ2xET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRThwNkO3OFYh|ryP NIW4PGdUSU6JRWK=
TE-10 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LITGlEPTB;OD63OlM2OyEQvF2= NH;zUGZUSU6JRWK=
LC-1F NGHETmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXT4W3F6UUN3ME25MlExQDN2IN88US=> Mo\BV2FPT0WU
OS-RC-2 NWPHPWUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzuTWM2OD17LkGxNlQ{KM7:TR?= M{\zW3NCVkeHUh?=
NCI-SNU-16 MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzq[IZLUUN3ME25MlIyODJ4IN88US=> MVrTRW5ITVJ?
SHP-77 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPobYs6UUN3ME25MlcyPjZ{IN88US=> NWG4bW1YW0GQR1XS
A4-Fuk MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHYUoVzUUN3ME25Mlc2PjFizszN MUXTRW5ITVJ?
NB6 NUP3V4dST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTlwN{[wNlkh|ryP M1PHUHNCVkeHUh?=
JiyoyeP-2003 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPzTWM2OD1zMD60O|Q2KM7:TR?= NHPS[XlUSU6JRWK=
DMS-114 NFXBSG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFyLkW0OFEh|ryP MULTRW5ITVJ?
NB7 Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4e1Z2lEPTB;MUCuO|UzPiEQvF2= MXHTRW5ITVJ?
NCI-H747 NF3TXWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[4SVZKSzVyPUGxMlEzOTZizszN NEDGVGtUSU6JRWK=
HH MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4qyUWlEPTB;MUGuN|g4PiEQvF2= Mm\5V2FPT0WU
EW-18 NYTQTVI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFzLkmwOFQh|ryP NFX2eHJUSU6JRWK=
CHP-126 NHvpcJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTFzLkm3N|gh|ryP NInzW|FUSU6JRWK=
NTERA-S-cl-D1 M4\1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvmTWM2OD1zMj6wNlc5KM7:TR?= MmjCV2FPT0WU
DEL NFzoXopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;tZXJKSzVyPUGyMlA6QDVizszN NIiydnNUSU6JRWK=
LU-139 M4ftPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTF{LkW0NVMh|ryP NFj1cmpUSU6JRWK=
P30-OHK M4LYfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rtZmlEPTB;MUKuOVQ4QSEQvF2= NYPr[nZvW0GQR1XS
NCI-H1522 MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fBZWlEPTB;MUKuO|Q3KM7:TR?= NFKxfmJUSU6JRWK=
NCI-H1299 M2TO[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTF|LkK5NVEh|ryP NHfFWnVUSU6JRWK=
UACC-257 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvQTWM2OD1zMz61NVI3KM7:TR?= NUDjdHQ1W0GQR1XS
Calu-6 M{XwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3xTWM2OD1zMz62NFQ3KM7:TR?= NVL3PXR[W0GQR1XS
NCI-H1882 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\OTWM2OD1zMz64OVU2KM7:TR?= M3TFPHNCVkeHUh?=
BB30-HNC NVTXfG43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPJU3hKSzVyPUG0MlA3ODlizszN MUnTRW5ITVJ?
ES1 M2j5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fUOGlEPTB;MUSuNVU2OSEQvF2= M1rMXnNCVkeHUh?=
NCI-H1694 NV71cnRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3O4d2lEPTB;MUSuOFgyOSEQvF2= MW\TRW5ITVJ?
IST-SL1 MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLnUmhKSzVyPUG0Mlk3OTZizszN NIe1Zm1USU6JRWK=
ECC4 M{Tx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TGOWlEPTB;MUWuNFU2QCEQvF2= MYXTRW5ITVJ?
MDA-MB-134-VI M{TmOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDtdHVEUUN3ME2xOU41OTNzIN88US=> Ml;5V2FPT0WU
SCH Mn7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEmy[m1KSzVyPUG1MlQ4OjhizszN M1HDdHNCVkeHUh?=
SK-N-FI M1jpU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF3Lk[1N|Qh|ryP NUjFTpJ6W0GQR1XS
HDLM-2 MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF4LkC3NVQh|ryP NV\2NoozW0GQR1XS
Ramos-2G6-4C10 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPQ[I46UUN3ME2xOk4yOjl5IN88US=> NV3yflFkW0GQR1XS
EW-24 NVrOdoU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrJR2FKSzVyPUG2MlE3PjFizszN NY\SfpFVW0GQR1XS
NCI-H2141 M4T5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPEeIZKSzVyPUG2MlE5QSEQvF2= M2n2enNCVkeHUh?=
LC4-1 NIfMdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXtV2txUUN3ME2xOk43OTF7IN88US=> MnW5V2FPT0WU
HT-144 Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\JWllKSzVyPUG3MlAxPiEQvF2= NYTzTJhwW0GQR1XS
SK-MEL-1 M4W2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjC[2RKSzVyPUG3MlAxPzJizszN NWfxR|RoW0GQR1XS
SCC-15 NEm1WG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHQc4lKSzVyPUG3MlE3OzhizszN NWW1c5p1W0GQR1XS
C8166 NWXnXoNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;vTWM2OD1zNz62PFM{KM7:TR?= MnrHV2FPT0WU
GOTO Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTINIZsUUN3ME2xO{45OzR2IN88US=> MXrTRW5ITVJ?
COR-L279 M{P6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHKfGViUUN3ME2xPE4yOzZ{IN88US=> NXfBV5dPW0GQR1XS
K-562 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PhfmlEPTB;MUiuO|E1OyEQvF2= MWrTRW5ITVJ?
ES3 NEDKfHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXQW|FKSzVyPUG4MlgxPDFizszN M{TpcHNCVkeHUh?=
LU-165 NHXOdm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTF7LkewNFgh|ryP M4XSZXNCVkeHUh?=
KM-H2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXWyWlFpUUN3ME2yNE4{OTh2IN88US=> NGPwPJhUSU6JRWK=
RL MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnkZZduUUN3ME2yNE46Pjl{IN88US=> MXjTRW5ITVJ?
EW-3 M2jIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Xab2lEPTB;MkGuNVg5QSEQvF2= M4PyWHNCVkeHUh?=
A101D Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i2[GlEPTB;MkGuN|c2OiEQvF2= NHjMTXVUSU6JRWK=
HUTU-80 NYXsbldOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;sd4I6UUN3ME2yNU4{QTR4IN88US=> MonkV2FPT0WU
NCI-H23 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\0TGlEPTB;MkGuN|k6OiEQvF2= M2HxdXNCVkeHUh?=
PF-382 NHzvXJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\USZpIUUN3ME2yNU41PDB|IN88US=> NHj6eIxUSU6JRWK=
LB373-MEL-D M3nRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXJOHJKSzVyPUKxMlU3OTVizszN NX\ZdpE4W0GQR1XS
TE-8 NGP6OpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJzLk[zPVQh|ryP NVS2NGw2W0GQR1XS
TE-9 M2n1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIOz[I1KSzVyPUKxMlg2OTNizszN NHTGO|NUSU6JRWK=
Daudi M1LUNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPENHVKSzVyPUKxMlk{ODRizszN MlnRV2FPT0WU
D-542MG NXnjUmhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJ{LkCyOVYh|ryP NHXUXoZUSU6JRWK=
U-698-M Mo\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJ{LkS2NFMh|ryP NHPRSpJUSU6JRWK=
ES6 M2KzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\VbGlEPTB;MkKuO|M3PiEQvF2= MYXTRW5ITVJ?
DU-4475 NFu1eI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\DTWM2OD1{Mz64PFk4KM7:TR?= MkT2V2FPT0WU
ECC12 NHuwOZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjleFJKSzVyPUK0MlI5ODNizszN MmrRV2FPT0WU
C2BBe1 NV7pTGI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrKdpRYUUN3ME2yOE4{OjN7IN88US=> Mk\zV2FPT0WU
IST-SL2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn0TWM2OD1{ND60N|YzKM7:TR?= MoGxV2FPT0WU
DJM-1 NV:4cIl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX22N41lUUN3ME2yOE42OjJzIN88US=> MUfTRW5ITVJ?
DMS-153 NVfVO4s4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3S3emlEPTB;MkSuPFYyPCEQvF2= MkK0V2FPT0WU
NB13 NF;6VmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEntVZZKSzVyPUK1MlAzPjVizszN M2fGe3NCVkeHUh?=
SK-N-DZ NWe2VVZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfNPGtKSzVyPUK2MlM1OTRizszN NIrpNWhUSU6JRWK=
COR-L88 NVexOmh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvUTWM2OD1{Nj61O|k3KM7:TR?= NWfEXI0yW0GQR1XS
LU-65 MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3ETWM2OD1{Nj64OVM2KM7:TR?= MnHBV2FPT0WU
TGBC1TKB NUX5coRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfuR3pbUUN3ME2yOk46QDJ6IN88US=> MV;TRW5ITVJ?
THP-1 MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLmSZpOUUN3ME2yO{4zOTRzIN88US=> M{n4O3NCVkeHUh?=
ONS-76 MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPNWnlJUUN3ME2yO{4{OzJizszN MXvTRW5ITVJ?
LC-2-ad NVS0W5NZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnKWINmUUN3ME2yO{43OjNzIN88US=> MXPTRW5ITVJ?
EW-13 M3r2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXL3cHFJUUN3ME2yPU4yPzR4IN88US=> NIXzT41USU6JRWK=
MS-1 NVTEOmtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTNyLkeyO|gh|ryP M1L6eHNCVkeHUh?=
NCI-H2227 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTNyLkm4NFYh|ryP NWi0d5RqW0GQR1XS
LXF-289 NV7wW25iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1riVmlEPTB;M{GuOFQ6OiEQvF2= MlLsV2FPT0WU
MC116 NEHye4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nwcmlEPTB;M{KuNFgzPiEQvF2= NUP3T4drW0GQR1XS
EVSA-T NUfRSHAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHhTWM2OD1|Mj6yOVg2KM7:TR?= NYjGPZJ3W0GQR1XS
CTB-1 NXLPNIJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvsTWM2OD1|Mz6xNVAyKM7:TR?= M3v3VnNCVkeHUh?=
COLO-320-HSR M3LHSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\0TWM2OD1|Mz6xOlA{KM7:TR?= NXX0c5F2W0GQR1XS
NCI-H2196 NIjDeoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjn[|RKSzVyPUOzMlI2PTdizszN MlzjV2FPT0WU
LB2241-RCC NF6wdnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEi1OoZKSzVyPUOzMlMyOzVizszN NUXyV5hXW0GQR1XS
LS-513 NYXmNlVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTN|Lki2N|gh|ryP NELJ[ZBUSU6JRWK=
LP-1 NWX5b4FjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTN|Lkm5OVYh|ryP NHf6UHFUSU6JRWK=
A253 MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmn6TWM2OD1|ND6yNlk3KM7:TR?= M1jFbHNCVkeHUh?=
SK-MM-2 M3Hl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjiZpVKSzVyPUO0Mlk1PTFizszN NIPjVHlUSU6JRWK=
NCI-H1963 MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTN3LkOwO|Ih|ryP MUDTRW5ITVJ?
MMAC-SF M1\2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;VTWM2OD1|NT64O|g2KM7:TR?= NF3wN25USU6JRWK=
LB831-BLC M{jSS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37PXGlEPTB;M{[uNFY2PCEQvF2= M3X4c3NCVkeHUh?=
WSU-NHL NXuwfFh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[zTWM2OD1|Nj6xOlQh|ryP NV32Xm5OW0GQR1XS
CESS NEfxPVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PNeGlEPTB;M{[uNlg1QCEQvF2= NHPYV|FUSU6JRWK=
NEC8 MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPY[2VKUUN3ME2zOk42QDN3IN88US=> NV2yTHppW0GQR1XS
KNS-42 MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTN5LkGyN|ch|ryP M17iWnNCVkeHUh?=
MHH-CALL-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\LNXFlUUN3ME2zO{4yQDJzIN88US=> Ml;3V2FPT0WU
K5 NVTD[4g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NES3OVNKSzVyPUO4MlQ{KM7:TR?= NYHOOIdqW0GQR1XS
CP66-MEL NXuwZ3dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTQTWM2OD1|OT6wO|M{KM7:TR?= NEfQTWNUSU6JRWK=
OPM-2 Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;STWM2OD1|OT64OFMzKM7:TR?= M1n3WnNCVkeHUh?=
IST-MES1 NIDjeVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3qR2ZTUUN3ME20NE4{ODl4IN88US=> MVjTRW5ITVJ?
EC-GI-10 MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrRU3NPUUN3ME20NU42QDB3IN88US=> NV7LdppQW0GQR1XS
CTV-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Tx[GlEPTB;NEKuPFQxPiEQvF2= MW\TRW5ITVJ?
DG-75 MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDRTWM2OD12Mz63OVk2KM7:TR?= NEnDW2pUSU6JRWK=
KNS-81-FD Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r6TmlEPTB;NEWuOFA2QCEQvF2= NUfUdoE6W0GQR1XS
NCI-H82 NY[ze3lrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LWNmlEPTB;NEWuOVc2QCEQvF2= NX3HXJZpW0GQR1XS
RPMI-8866 NU[wT3pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnwfINKSzVyPUS2MlE5PzNizszN MW\TRW5ITVJ?
ACN NUPTS|FbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33H[2lEPTB;NE[uOFM1KM7:TR?= M{HFUHNCVkeHUh?=
NCI-H1395 Mke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPoboVKSzVyPUS2MlQ4PTZizszN M3j2fHNCVkeHUh?=
NCI-H209 NEnTbmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYiycnh1UUN3ME20O{4yPDB3IN88US=> NUnOXodOW0GQR1XS
TGW NFTpfoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fNZ2lEPTB;NEmuNFc6OSEQvF2= NGnuVoFUSU6JRWK=
NCI-H748 NYXUVoN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3hOpJ5UUN3ME20PU41PzV|IN88US=> NXHrWY5[W0GQR1XS
EKVX MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTR7Lk[2Nlgh|ryP NVrhZ3VmW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Biochemical assays:

Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
Cell Research:

[1]

+ Expand
  • Cell lines: MDA-MB-231, and HAoSMC
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
  • Formulation: Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4 × stock solution, and diluted to 1 × with water
  • Dosages: ~60 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL warmed (135.53 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+45% PEG 400+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 464.82
Formula

C21H16ClF3N4O3

CAS No. 284461-73-0
Storage powder
Synonyms BAY 43-9006

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00727233 Completed Neurofibromatosis Type I|Plexiform Neurofibroma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 8, 2008 Phase 1
NCT02989870 Not yet recruiting HepatoCellular Carcinoma|Unresectable HepatoCellular Carcinoma|Liver Cancer H. Lee Moffitt Cancer Center and Research Institute|National Comprehensive Cancer Network April 30, 2017 Phase 1
NCT01445080 Completed Leukemia|With AML and FLT3-ITD Mutations National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 23, 2006 Phase 1
NCT01434602 Recruiting Brain Tumor|Glioblastoma|Anaplastic Glioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 21, 2015 Phase 1|Phase 2
NCT02988440 Not yet recruiting Hepatocellular Carcinoma Novartis Pharmaceuticals|Novartis May 2017 Phase 1
NCT03037437 Not yet recruiting Hepatocellular Cancer The University of Texas Health Science Center at San Antonio January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Raf Signaling Pathway Map

Related Raf Products

Tags: buy Sorafenib | Sorafenib supplier | purchase Sorafenib | Sorafenib cost | Sorafenib manufacturer | order Sorafenib | Sorafenib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID